Ludigs Kristina, Seguín-Estévez Queralt, Lemeille Sylvain, Ferrero Isabel, Rota Giorgia, Chelbi Sonia, Mattmann Chantal, MacDonald H Robson, Reith Walter, Guarda Greta
Department of Biochemistry, University of Lausanne, Epalinges, Switzerland.
Department of Pathology and Immunology, University of Geneva Medical School, Geneva, Switzerland.
PLoS Genet. 2015 Mar 26;11(3):e1005088. doi: 10.1371/journal.pgen.1005088. eCollection 2015 Mar.
MHC class II (MHCII) genes are transactivated by the NOD-like receptor (NLR) family member CIITA, which is recruited to SXY enhancers of MHCII promoters via a DNA-binding "enhanceosome" complex. NLRC5, another NLR protein, was recently found to control transcription of MHC class I (MHCI) genes. However, detailed understanding of NLRC5's target gene specificity and mechanism of action remained lacking. We performed ChIP-sequencing experiments to gain comprehensive information on NLRC5-regulated genes. In addition to classical MHCI genes, we exclusively identified novel targets encoding non-classical MHCI molecules having important functions in immunity and tolerance. ChIP-sequencing performed with Rfx5(-/-) cells, which lack the pivotal enhanceosome factor RFX5, demonstrated its strict requirement for NLRC5 recruitment. Accordingly, Rfx5-knockout mice phenocopy Nlrc5 deficiency with respect to defective MHCI expression. Analysis of B cell lines lacking RFX5, RFXAP, or RFXANK further corroborated the importance of the enhanceosome for MHCI expression. Although recruited by common DNA-binding factors, CIITA and NLRC5 exhibit non-redundant functions, shown here using double-deficient Nlrc5(-/-)CIIta(-/-) mice. These paradoxical findings were resolved by using a "de novo" motif-discovery approach showing that the SXY consensus sequence occupied by NLRC5 in vivo diverges significantly from that occupied by CIITA. These sequence differences were sufficient to determine preferential occupation and transactivation by NLRC5 or CIITA, respectively, and the S box was found to be the essential feature conferring NLRC5 specificity. These results broaden our knowledge on the transcriptional activities of NLRC5 and CIITA, revealing their dependence on shared enhanceosome factors but their recruitment to distinct enhancer motifs in vivo. Furthermore, we demonstrated selectivity of NLRC5 for genes encoding MHCI or related proteins, rendering it an attractive target for therapeutic intervention. NLRC5 and CIITA thus emerge as paradigms for a novel class of transcriptional regulators dedicated for transactivating extremely few, phylogenetically related genes.
MHC II类(MHCII)基因由NOD样受体(NLR)家族成员CIITA反式激活,CIITA通过DNA结合“增强体”复合物被招募到MHCII启动子的SXY增强子上。另一种NLR蛋白NLRC5最近被发现可控制MHC I类(MHCI)基因的转录。然而,对NLRC5的靶基因特异性及其作用机制仍缺乏详细了解。我们进行了染色质免疫沉淀测序(ChIP-seq)实验,以获取有关NLRC5调控基因的全面信息。除了经典的MHCI基因外,我们还专门鉴定了编码在免疫和耐受中具有重要功能的非经典MHCI分子的新靶标。对缺乏关键增强体因子RFX5的Rfx5(-/-)细胞进行的ChIP-seq实验表明,RFX5对NLRC5的招募有严格要求。因此,Rfx5基因敲除小鼠在MHCI表达缺陷方面模拟了Nlrc5缺陷。对缺乏RFX5、RFXAP或RFXANK的B细胞系的分析进一步证实了增强体对MHCI表达的重要性。尽管CIITA和NLRC5由共同的DNA结合因子招募,但它们表现出非冗余功能,这在使用双缺陷的Nlrc5(-/-)CIIta(-/-)小鼠的实验中得到了证明。通过使用“从头”基序发现方法解决了这些矛盾的发现,该方法表明NLRC5在体内占据的SXY共有序列与CIITA占据的序列有显著差异。这些序列差异足以分别决定NLRC5或CIITA的优先占据和反式激活,并且发现S盒是赋予NLRC5特异性的关键特征。这些结果拓宽了我们对NLRC5和CIITA转录活性的认识,揭示了它们对共享增强体因子的依赖性,但它们在体内被招募到不同的增强子基序上。此外,我们证明了NLRC5对编码MHCI或相关蛋白的基因具有选择性,使其成为治疗干预的有吸引力的靶点。因此,NLRC5和CIITA成为一类新型转录调节因子的范例,这类调节因子专门用于反式激活极少数系统发育相关的基因。